Related Experiment Videos
The price of autonomy
Michael Baum1, Jayant S. Vaidya
1Department of Surgery, Institute of Surgical Studies, University College London, 67-73 Riding House Street, London, UK.
Summary
The ethical conflict between informed consent and patient benefit in clinical trials may delay life-saving treatments. This study quantifies the potential cost in lives due to prioritizing autonomy in cancer research.
Area of Science:
- Medical Ethics
- Clinical Trial Design
- Public Health Policy
Background:
- Randomized controlled trials (RCTs) present ethical dilemmas, particularly the conflict between informed consent (autonomy) and the principles of beneficence and justice.
- Informed consent processes are a significant barrier to patient recruitment in clinical trials, thereby delaying the development of crucial medical treatments.
Purpose of the Study:
- To challenge the prevailing ethical dogma by quantifying the 'price of autonomy' in clinical research.
- To estimate the number of lives potentially lost over a decade due to recruitment delays caused by informed consent requirements in cancer trials.
Main Methods:
- Development of a decision-making model with explicit assumptions.
- Utilization of a mathematical equation to calculate the cost in lives based on conservative estimates.
- Focus on breast cancer as a case study for the model's application.
Main Results:
- Conservative assumptions estimate that the prioritization of autonomy in clinical trials could cost approximately 2,500 lives over a 10-year period in the United Kingdom alone.
- The study highlights the indirect but significant impact of informed consent on patient outcomes and treatment advancement.
Conclusions:
- There is a critical need for health policymakers and ethicists to re-evaluate the balance between autonomy and collective benefit in clinical research.
- Public opinion surveys are recommended to determine societal valuation of autonomy in the context of life-saving cancer research and treatment development.